A Phase 3 interventional study of MenACYW conjugate vaccine in Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 8 sites in Finland. Open to participants aged 46 Months to 61 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Among 53 studies in Meningococcal Infections by Sanofi Pasteur, a Sanofi Company — 1 open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · Sanofi Pasteur, a Sanofi Company.
Among the 53 studies in Meningococcal Infections by Sanofi Pasteur, a Sanofi Company, this one is the 45th largest by enrollment of the 47 interventional ones, is one of 7 that started in 2018, is one of 22 in phase 3, and was the 43rd registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
This study's enrollment of 91 is below the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Browse Meningococcal Infections studies →1 of the 53 studies in Meningococcal Infections by Sanofi Pasteur, a Sanofi Company is open now, in 1 country. Each count lists the studies.
Of the 7 Meningococcal Infections studies recruiting now, 3 (43%) set no upper age limit and 4 (57%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 46 Months to 61 Months · all sexes · healthy volunteers too.
The full table on the hub →53 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2018.
Median enrollment 378 across the 47 interventional studies, 440 across the 6 observational. Of the 52 that completed or were terminated, 49 (94%) have results posted.
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 53 studies in Meningococcal Infections by Sanofi Pasteur, a Sanofi Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This was an open-label, multi-center study to describe the immune persistence of the priming dose and describe the immunogenicity and safety of a booster dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) conjugate vaccine in children in Finland who had been vaccinated 3 years earlier as toddlers with either MenACYW conjugate vaccine or Nimenrix® as part of the MET54 study (NCT03205358).
The objectives were:
Healthy children who were vaccinated 3 years earlier at 12 to 23 months of age in study MET54 (NCT03205358) were eligible for enrollment. All participants received a single booster dose of MenACYW conjugate vaccine on Day 0. Immunogenicity was assessed at pre-vaccination and 30 days after vaccination. Safety was assessed throughout the study period, and included solicited injection site and systemic reactions (Day 0 to Day 7 post-vaccination); unsolicited adverse events up to Day 30 (Visit 2), and serious adverse events occurring throughout the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
Biological: MenACYW conjugate vaccine
Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
Biological: MenACYW conjugate vaccine
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
Antibody Titers Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW Conjugate Vaccine in MET62
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 0 (pre-vaccination)
Antibody Titers Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After a Booster Dose of MenACYW Conjugate Vaccine in MET62
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 30 (post-booster vaccination)
Antibody Titers Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW Conjugate Vaccine in MET62
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.
Time frame: Day 0 (pre-vaccination)
Antibody Titers Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After a Booster Dose of MenACYW Conjugate Vaccine in MET62
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.
Time frame: Day 30 (post-booster vaccination)
Antibody Titers Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Priming Vaccination in MET54 and Booster Vaccination in MET62
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-priming vaccination) in study MET54, and Day 0 (pre-vaccination) and Day 30 (post-booster vaccination) in study MET62
Antibody Titers Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Priming Vaccination in MET54 and Booster Vaccination in MET62
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.
Time frame: Day 0 (pre-vaccination) and Day 30 (post-priming vaccination) in study MET54, and Day 0 (pre-vaccination) and Day 30 (post-booster vaccination) in study MET62
Antibody Concentrations Against Tetanus Toxoid Before a Booster Dose of MenACYW Conjugate Vaccine in MET62
Anti-tetanus antibodies were measured by electrochemiluminescent (ECL) assay.
Time frame: Day 0 (pre-vaccination)
Antibody Concentrations Against Tetanus Toxoid After a Booster Dose of MenACYW Conjugate Vaccine in MET62
Anti-tetanus antibodies were measured by ECL assay.
Time frame: Day 30 (post-booster vaccination)
Number of Participants With Immediate Adverse Event After Vaccination in MET62
Immediate events captured medically relevant unsolicited systemic adverse events (AEs) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.
Time frame: Within 30 minutes after vaccination
Number of Participants With Solicited Injection Site Reactions and Systemic Reactions in MET62
A solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: fever, headache, malaise and, myalgia.
Time frame: Within 7 days after vaccination
Number of Participants With Unsolicited Adverse Event After Vaccination in MET62
An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination.
Time frame: Within 30 days after vaccination
Number of Participants With a Serious Adverse Event (SAE) After Vaccination in MET62
A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event.
Time frame: Within 30 days after vaccination
The study was conducted at 8 sites in Finland from 27 February 2018 to 10 September 2018.
| Milestone | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Started | 42 | 49 |
| Completed | 42 | 49 |
| Not completed | 0 | 0 |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Serogroup A | 12.1 (8.15 to 18.1) | 16.5 (11.9 to 22.9) |
| Serogroup C | 106 (73.2 to 153) | 11.7 (7.03 to 19.4) |
| Serogroup Y | 30.9 (24.2 to 39.5) | 17.6 (13.1 to 23.7) |
| Serogroup W | 48.5 (34.4 to 68.4) | 21.9 (14.7 to 32.7) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Serogroup A | 763 (521 to 1117) | 659 (427 to 1017) |
| Serogroup C | 5894 (4325 to 8031) | 1592 (1165 to 2174) |
| Serogroup Y | 2013 (1451 to 2792) | 2806 (2066 to 3813) |
| Serogroup W | 2656 (1601 to 4406) | 3444 (2387 to 4970) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.
| titers (1/dilution) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Serogroup A | 135 (58.0 to 314) | 281 (131 to 606) |
| Serogroup C | 102 (60.9 to 169) | 11.9 (6.14 to 22.9) |
| Serogroup Y | 119 (65.0 to 219) | 126 (69.1 to 230) |
| Serogroup W | 113 (54.6 to 234) | 126 (63.6 to 250) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.
| titers (1/dilution) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Serogroup A | 4240 (3352 to 5365) | 5702 (4575 to 7107) |
| Serogroup C | 8629 (6573 to 11328) | 4871 (3750 to 6327) |
| Serogroup Y | 5499 (4502 to 6717) | 7814 (6465 to 9445) |
| Serogroup W | 16103 (12691 to 20431) | 19793 (15538 to 25214) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Serogroup A: Day 0 (MET54) | 3.68 (3.12 to 4.33) | 3.67 (3.15 to 4.29) |
| Serogroup A: Day 30 (MET54) | 83.3 (63.9 to 109) | 49.6 (32.1 to 76.7) |
| Serogroup A: Day 0 (MET62) | 11.9 (8.11 to 17.4) | 14.7 (10.7 to 20.2) |
| Serogroup A: Day 30 (MET62) | 755 (520 to 1097) | 629 (418 to 948) |
| Serogroup C: Day 0 (MET54) | 2.48 (2.04 to 3.01) | 2.30 (2.12 to 2.50) |
| Serogroup C: Day 30 (MET54) | 594 (445 to 793) | 29.4 (20.1 to 43.1) |
| Serogroup C: Day 0 (MET62) | 103 (71.7 to 149) | 11.6 (7.28 to 18.3) |
| Serogroup C: Day 30 (MET62) | 5744 (4230 to 7800) | 1618 (1204 to 2172) |
| Serogroup Y: Day 0 (MET54) | 2.17 (1.95 to 2.42) | 2.27 (2.05 to 2.52) |
| Serogroup Y: Day 30 (MET54) | 105 (73.9 to 149) | 75.8 (54.2 to 106) |
| Serogroup Y: Day 0 (MET62) | 32.5 (24.8 to 42.7) | 18.2 (13.8 to 24.0) |
| Serogroup Y: Day 30 (MET62) | 2048 (1486 to 2823) | 2710 (2022 to 3633) |
| Serogroup W: Day 0 (MET54) | 2.00 (NA to NA) | 2.12 (2.00 to 2.24) |
| Serogroup W: Day 30 (MET54) | 71.8 (53.3 to 96.7) | 40.1 (30.6 to 52.6) |
| Serogroup W: Day 0 (MET62) | 50.0 (35.9 to 69.5) | 21.2 (14.6 to 30.9) |
| Serogroup W: Day 30 (MET62) | 2776 (1682 to 4584) | 3235 (2278 to 4594) |
Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.
| titers (1/dilution) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Serogroup A: Day 0 (MET54) | 12.3 (5.25 to 28.8) | 4.88 (2.74 to 8.69) |
| Serogroup A: Day 30 (MET54) | 3198 (2559 to 3996) | 7633 (5879 to 9909) |
| Serogroup A: Day 0 (MET62) | 124 (54.0 to 283) | 239 (113 to 503) |
| Serogroup A: Day 30 (MET62) | 4096 (3223 to 5205) | 5341 (4275 to 6674) |
| Serogroup C: Day 0 (MET54) | 2.21 (1.81 to 2.70) | 2.15 (1.86 to 2.47) |
| Serogroup C: Day 30 (MET54) | 2711 (2156 to 3409) | 414 (283 to 607) |
| Serogroup C: Day 0 (MET62) | 94.4 (55.9 to 160) | 11.2 (6.11 to 20.6) |
| Serogroup C: Day 30 (MET62) | 8474 (6483 to 11075) | 4817 (3759 to 6175) |
| Serogroup Y: Day 0 (MET54) | 2.88 (1.87 to 4.42) | 4.29 (2.48 to 7.44) |
| Serogroup Y: Day 30 (MET54) | 2667 (2063 to 3447) | 2836 (2127 to 3781) |
| Serogroup Y: Day 0 (MET62) | 120 (67.1 to 213) | 123 (67.6 to 223) |
| Serogroup Y: Day 30 (MET62) | 5553 (4565 to 6755) | 7498 (6213 to 9049) |
| Serogroup W: Day 0 (MET54) | 2.00 (NA to NA) | 2.24 (1.78 to 2.81) |
| Serogroup W: Day 30 (MET54) | 5793 (4346 to 7720) | 4214 (3162 to 5616) |
| Serogroup W: Day 0 (MET62) | 106 (51.6 to 219) | 113 (57.9 to 219) |
| Serogroup W: Day 30 (MET62) | 15839 (12530 to 20023) | 18710 (14737 to 23753) |
Anti-tetanus antibodies were measured by electrochemiluminescent (ECL) assay.
| International unit per milliliter(IU/mL) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Antibody Concentrations Against Tetanus Toxoid Before a Booster Dose of MenACYW Conjugate Vaccine in MET62 | 3.12 (2.05 to 4.75) | 3.02 (2.11 to 4.31) |
Anti-tetanus antibodies were measured by ECL assay.
| IU/mL | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Antibody Concentrations Against Tetanus Toxoid After a Booster Dose of MenACYW Conjugate Vaccine in MET62 | 10.4 (8.41 to 12.8) | 9.36 (7.61 to 11.5) |
Immediate events captured medically relevant unsolicited systemic adverse events (AEs) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.
| Participants | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Number of Participants With Immediate Adverse Event After Vaccination in MET62 | 0 | 0 |
A solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: fever, headache, malaise and, myalgia.
| Participants | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Pain | 26 | 35 |
| Erythema | 22 | 27 |
| Swelling | 16 | 19 |
| Fever | 3 | 4 |
| Headache | 8 | 14 |
| Malaise | 13 | 15 |
| Myalgia | 14 | 21 |
An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination.
| Participants | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Number of Participants With Unsolicited Adverse Event After Vaccination in MET62 | 22 | 15 |
A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event.
| Participants | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Number of Participants With a Serious Adverse Event (SAE) After Vaccination in MET62 | 0 | 0 |
Collected over SR were collected up to Day 7 after each vaccination, non-serious unsolicited AEs were collected up to Day 30 after each vaccination. SAEs were collected throughout the trial (up to 30 days after vaccination).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | 0/42 (0%) | 0/42 (0%) | 36/42 (85.7%) |
| Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) | 0/49 (0%) | 0/49 (0%) | 43/49 (87.8%) |
| Event | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) |
|---|---|---|
| Injection Site PainGeneral disorders | 26/42 | 35/49 |
| Injection Site ErythemaGeneral disorders | 22/42 | 27/49 |
| MyalgiaMusculoskeletal and connective tissue disorders | 14/42 | 21/49 |
| Injection Site SwellingGeneral disorders | 16/42 | 19/49 |
| MalaiseGeneral disorders | 13/42 | 15/49 |
| HeadacheNervous system disorders | 10/42 | 14/49 |
| Upper Respiratory Tract InfectionInfections and infestations | 7/42 | 4/49 |
| PyrexiaGeneral disorders | 3/42 | 4/49 |
| Otitis MediaInfections and infestations | 1/42 | 3/49 |
Analysis was performed on all enrolled participants.
| Age, Continuous(years) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) | Total |
|---|---|---|---|
| Mean | 3.9 ± 0.35 | 3.9 ± 0.33 | 3.9 ± 0.34 |
| Sex: Female, Male(Participants) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) | Total |
|---|---|---|---|
| Female | 16 | 30 | 46 |
| Male | 26 | 19 | 45 |
| Race and Ethnicity Not Collected(Participants) | Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW) | Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2018 to primary completion in Sep 2018, 6 months.
Results were first posted in Jun 2020, 1 year 8 months after primary completion. A results delay was requested in Sep 2019.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 6 months is below that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →